Rapid Dose Issues Q1 2020 Financial Results

- July 30th, 2019

Rapid Dose Therapeutics (CSE:DOSE) released its financial results for Q1 of the fiscal 2020 year. As quoted in the press release: “This quarter represents a very exciting milestone for RDT as we commence the recognition of revenues from initial sales of our Energy, Vitamin B12, and Sleep QuickStrip™ nutraceutical products,” said Mark Upsdell, CEO of RDT. “Revenues from … Continued

Rapid Dose Therapeutics (CSE:DOSE) released its financial results for Q1 of the fiscal 2020 year.

As quoted in the press release:

“This quarter represents a very exciting milestone for RDT as we commence the recognition of revenues from initial sales of our Energy, Vitamin B12, and Sleep QuickStrip™ nutraceutical products,” said Mark Upsdell, CEO of RDT. “Revenues from the delivery of QuickStrip™ production equipment and recurring revenues for cannabis products will begin in Q2.”

First Quarter Highlights

  • Commencement of revenue recognition from the sale of QuickStrip™ nutraceutical products

  • Appointment of Mr. Ian Fodie as Chief Financial Officer

  • Signing of Distribution Agreement with TFB & Associates Ltd. for QuickStrip™ nutraceutical products in Canada

  • Signing of Memorandum of Understanding with Thrive Cannabis providing Thrive the right to sell RDT’s proprietary QuickStripTM technology using cannabis distillate in Canada

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our new report today
 

Get the latest Cannabis Investing stock information

Get the latest information about companies associated with Cannabis Investing Delivered directly to your inbox.

Cannabis Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *